|Bid||4.10 x 2900|
|Ask||7.76 x 1800|
|Day's Range||5.21 - 5.55|
|52 Week Range||5.20 - 14.62|
|Beta (3Y Monthly)||3.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.29|
Adaptimmune Therapeutics plc (NASDAQ:ADAP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ADAP Read More...
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells.
PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial.
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Shares of Adaptimmune Therapeutics PLC slumped 21% in morning trade Monday, after the results from a trial of its cancer treatment prompted Raymond James to slash its price target. The biopharmaceutical company said over the weekend that it was encouraged by the safety data from ongoing studies of SPEAR T-cells, but said no patients were treated in a Cohort 2 "triple tumor" study because the Safety Review Committee recommended an escalated dose. Raymond James analyst Reni Benjamin cut his target to $16 from $20, as the true efficacy of the product may only be determined at the higher, 5-billion-cell dose level. "Although still early, we believe higher doses will likely need to be evaluated with a larger population," Benjamin wrote in a note to clients. "We are decreasing our probability of success from 35% to 25% as we await a stronger correlation between dose, persistence, and clinical response." The stock has slumped 19% over the past three months but was still up 27% year to date, while the S&P 500 has slipped 1.2% the past three months and has gained 3.6% this year.
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today.
If you’re interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Adaptimmune Therapeutics plc (“Adaptimmune”) (ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”). Adaptimmune sold 10,000,000 ADSs at a price of $10.00 per ADS. A shelf registration statement on Form S-3 relating to the public offering of the ADSs described above was filed with the Securities and Exchange Commission (“SEC”) and became effective on July 12, 2018.
Adaptimmune Therapeutics plc (“Adaptimmune”) (ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”), New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. (“NEA”) and Syncona Portfolio Limited (“Syncona”), to purchase an aggregate of US$100 million of its American Depositary Shares (“ADSs”) in a registered direct offering. The transaction was completed from the company’s shelf registration at a price of $10.00 per ADS. Net proceeds of the offering will be used to advance the company’s wholly owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes.
On August 24, Adaptimmune Therapeutics (ADAP) stock closed at $10.25, which represents a ~21% growth from its previous week’s closing price of $8.48 on August 17.
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Adaptimmune Therapeutics PLC Sponsored ADR (NASDAQ: ADAP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 ...